Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BKM120
BKM120+ MEK162 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| BKM120 + MEK162 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BKM120 + MEK162 | DRUG | - |
Inclusion Criteria: * Histologically/ cytologically confirmed, advanced non resectable solid tumors * Measurable or non-measurable, but evaluable disease as determined by RECIST Exclusion Criteria: * Patients with primary CNS tumor or CNS tumor involvement. * Diabetes mellitus * Unacceptable ocul...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BKM120 + MEK162 is an investigational combination of two small molecule drugs studied together in oncology. It was tested in patients with selected advanced solid tumors. The combination is not approved and remains in clinical development. It was evaluated in a single Phase 1 trial that has been completed.
BKM120 + MEK162 was studied for the treatment of selected advanced solid tumors. The Phase 1 trial enrolled patients with advanced solid tumors and selected solid tumor types. It is an investigational combination and is not an approved treatment for any indication.
BKM120 + MEK162 is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company associated with the development of this drug combination. The combination was evaluated in a single Phase 1 clinical trial.
BKM120 + MEK162 is in Phase 1 development. The only trial of this combination was a Phase 1 study, and it has been completed. The combination is investigational and has not been approved by the FDA for any indication.
BKM120 + MEK162 was studied in one clinical trial, NCT01363232, titled Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients. That Phase 1 trial is completed and enrolled 89 patients across the United States, Canada, Germany, Netherlands, Singapore, Spain, and Switzerland.
BKM120 + MEK162 is a combination regimen that includes BKM120, so searches for BKM120 may refer to this combination study. The trial NCT01363232 evaluated BKM120 plus MEK162 together in patients with selected advanced solid tumors. BKM120 + MEK162 is also written as BKM120 + MEK162.